Year-long support needed after stopping weight loss injections says NICE

Key Takeaways: 

• NICE advises that people stopping GLP-1 receptor agonist weight loss injections should receive at least 12 months of structured follow-up support to help maintain weight loss and associated health benefits.
• Experts welcome the recommendation but warn that NHS capacity and resources may be insufficient to deliver consistent, nationwide “wraparound” care.
• Around 1.5 million people in the UK are thought to be using weight loss injections, with an estimated 240,000 expected to be offered tirzepatide (Mounjaro) on the NHS within the next three years.
  

NICE Urges Long-Term Support After Weight Loss Treatment

The National Institute for Health and Care Excellence (NICE) has updated its guidance to recommend that people who stop taking weight loss injections receive structured advice and ongoing support for at least a year. The aim is to ensure that the benefits achieved through treatment—both weight loss and related health improvements—are maintained over the long term.

NICE’s advice applies to people coming off glucagon-like peptide-1 receptor agonist (GLP-1RA) medications such as semaglutide (Wegovy) and tirzepatide (Mounjaro). These drugs work by mimicking the GLP-1 hormone, which helps regulate appetite and food intake.

Without continued support, the risk of regaining lost weight is high. Studies suggest that about four in five people who discontinue these medications regain the weight they lost once their prescription ends.

Implementation Challenges and NHS Capacity

While the update has been welcomed by obesity care experts, there is widespread concern about whether the NHS has the resources to deliver such long-term, structured follow-up.

Around 1.5 million people in the UK are estimated to be using weight loss injections, and NHS England plans to offer tirzepatide to approximately 240,000 people over the next three years. The scale of potential demand raises questions about the availability of trained staff, access to services, and consistency of care across different regions.

Almost one-third (29%) of adults in England have obesity, and 64% are categorised as overweight or obese. Obesity is estimated to cost the NHS £11.4 billion annually through its impact on related health conditions.

Details of the Guidance

NICE states that general practitioners (GPs) and specialist overweight and obesity services must have clear protocols for supporting people once their prescription ends or they are discharged from treatment. The support should be designed to help individuals maintain lifestyle changes, prevent weight regain, and preserve associated health benefits.

The recommended interventions may include practical advice from initiatives such as NHS Better Health, tailored strategies to adapt daily habits, and adjustments in home or work environments to support healthier choices.

NICE also advises that if a patient approaches their GP for similar guidance after using a weight loss drug obtained privately, the GP should provide appropriate support or make a referral. However, NICE notes that such cases are expected to be uncommon.

Expert Perspectives

Jonathan Benger, Deputy Chief Executive and Chief Medical Officer at NICE, emphasised the importance of continuity in care:

“Successful weight management doesn’t end when medication stops or when someone completes a behavioural programme. We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they’ve made.”

Obesity UK welcomed the recognition of the need for ongoing care but expressed doubt about the NHS’s ability to implement it effectively. Alison Forster, Operations Manager at Obesity UK, commented:

“We remain concerned about the limited resourcing of NHS weight management services and the significant variability in access and provision across the country. This guidance just doesn’t go far enough.

Many of the people we support face long waits, inconsistent care pathways, and a lack of psychological and social support—issues that are not sufficiently addressed by the current system.

We know from existing evidence that about 80% of people will regain the weight once they come off the medication, and wraparound care is what is lacking after someone has stopped.”

Positive Direction but Further Reform Needed

Nicola Heslehurst, President of the Association for the Study of Obesity and an expert in maternal and child nutrition at Newcastle University, welcomed the move:

“It is a really positive move in the right direction to see the recognition that longer term support is required for managing obesity beyond short term programmes, whether these are medication or weight management programmes.”

However, she highlighted the need for structural changes in service commissioning:

“The lack of continued support has been a major flaw in service commissioning and delivery to date.”

The Role of General Practice and Broader Obesity Care

Kamila Hawthorne, Chair of the Royal College of General Practitioners, said:

“Patients will likely need support to sustain their weight loss once they stop taking the medication. As such, this is important and sensible guidance from NICE.

As a college we’ve been clear that whilst weight loss medications have significant potential benefits for patients who are struggling to lose weight, they mustn’t be seen as a ‘silver bullet,’ and ensuring access to sufficient ‘wraparound’ services—particularly for when patients come off their medication—will be key to optimal health outcomes. It’s vital that the rollout of weight loss medications as a treatment for obesity does not come at the expense of other weight loss services.”

Government Strategy

Expanding access to GLP-1RAs forms part of the UK government’s 10-year NHS plan to tackle obesity. This strategy aims not only to provide effective treatment options but also to integrate them within a broader system of ongoing care and prevention, ensuring that people who achieve weight loss have the resources to maintain it in the long term.

CCH Insight:

This new guidance from NICE seems, at first, like a sensible idea… until you think about how these drugs are meant to be used, and the evidence available for weight regain. GLP-1-based medications are meant to be used as an adjunct to diet and lifestyle support. So patients should be receiving the type of advice advocated by NICE whilst taking the drugs, not after they stop. By the time a patient stops taking the medication, they should have already established healthier eating and lifestyle habits.

If they have not done so by then, it is probably too late – because you are then asking people to eat more healthily just as their appetite and cravings are increasing after ceasing their medication. The other issue is that the current evidence, from clinical trials, suggests that lifestyle interventions DO NOT prevent weight regain after cessation of these drugs. NICE appear to be ignoring this evidence – why? Because the inconvenient truth is that obesity is a chronic relapsing condition, and many people with the condition may need to continue GLP-1 therapy for life if they are to maintain weight loss and health benefits it brings. NICE probably don’t like the implications of this in terms of cost, but it would actually save money in the long run through prevention of obesity-related complications.